BeOne Medicines earnings release, May 6, 2026

BeOne Medicines Ltd. (ONC) · Form 8-K, Item 2.02 · Filed · SEC filing

BeOne Medicines Announces First Quarter 2026 Financial Results and Business Updates

• Total global revenues of $1.5 billion for the first quarter, an increase of 35% from the prior year

• Foundational BRUKINSA (zanubrutinib) global revenues of $1.1 billion for the first quarter, an increase of 38% from the prior year

• Diluted GAAP Earnings per American Depository Share (ADS) of $1.96 for the first quarter; non-GAAP diluted Earnings per ADS of $3.24 for the first quarter

SAN CARLOS, Calif. – May 6, 2026 – BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced financial results and corporate updates from the first quarter of 2026.

John V. Oyler, Co-Founder, Chairman, and CEO, BeOne, said:

“These strong first-quarter results reinforce BeOne’s continued growth as a global oncology leader, driven by disciplined commercial execution, and underpinned by our established hematology leadership, and an impressive, rapidly emerging solid tumor pipeline. The sustained competitive advantages of our global superhighway for clinical development and manufacturing are now clear. BRUKINSA has firmly established itself as the foundational, best-in-class BTK inhibitor with unmatched long-term efficacy and safety data for the treatment of CLL and as the only BTKi with proven efficacy superiority over ibrutinib which has resulted in clear global revenue leadership. The fixed-duration combination of sonrotoclax, a foundational, next-generation BCL2 inhibitor, and BRUKINSA represents a potential new standard-of-care in first-line CLL, with BTK CDAC BGB-16673 emerging as a potential first-in-class therapy in the relapsed or refractory setting. With more than 20 abstracts across our hematology and solid tumor pipeline accepted for presentation at ASCO, BeOne has solidified its position as a leading oncology company.”

(Amounts in thousands of U.S. dollars and unaudited)

* For an explanation of our use of non-GAAP financial measures, refer to the “Note Regarding Use of Non-GAAP Financial Measures” section later in this press release and for a reconciliation of each non-GAAP financial measure to the most comparable GAAP measures, see the table at the end of this press release.

First Quarter 2026 Financial Results

Product Revenue totaled $1.5 billion for the first quarter of 2026, representing growth of 34% compared to the prior-year period.

• BRUKINSA: Global sales totaled $1.1 billion for the first quarter of 2026, representing growth of 38% compared to the prior-year period; U.S. sales of BRUKINSA totaled $761 million in the first quarter of 2026, representing growth of 35% compared to the prior-year period.

• TEVIMBRA (tislelizumab): Global sales totaled $206 million in the first quarter of 2026, representing growth of 20% compared to the prior-year period.

• Amgen in-licensed products: Global sales totaled $142 million in the first quarter of 2026, representing growth of 25% compared to the prior-year period.

Gross Margin as a percentage of global product sales for the first quarter of 2026 was 89%, compared to 85% in the prior-year period on a GAAP basis. The gross margin percentage increased due to a proportionally higher sales mix of global BRUKINSA compared to other products in our portfolio. Gross margin also benefited from productivity improvements resulting in lower costs for both BRUKINSA and TEVIMBRA.

Operating Expenses

The following table summarizes operating expenses for the first quarter of 2026:

Research and Development (R&D) Expenses increased for the first quarter of 2026 compared to the prior-year period on both a GAAP and adjusted basis due to advancing preclinical programs into the clinic and early clinical programs into late stage.

Selling, General and Administrative (SG&A) Expenses increased for the first quarter of 2026 compared to the prior-year period on both a GAAP and adjusted basis due to continued investment to support commercial growth. SG&A expenses as a percentage of product sales were 37% for the first quarter of 2026, compared to 41% in the prior-year period.

Net Income and Basic/Diluted Earnings Per Share

GAAP net income for the first quarter of 2026 was $227 million, an increase of $226 million over the prior-year period, primarily attributable to revenue growth and improved operating leverage.

For the first quarter of 2026, basic and diluted earnings per share were $0.16 and $0.15 per share and $2.05 and $1.96 per American Depositary Share (ADS), compared to basic and diluted earnings per share of $0.00 per share and $0.01 per ADS in the prior-year period.

Free Cash Flow for the first quarter of 2026 was $161 million, representing an increase of $173 million over the prior-year period.

For further details on BeOne’s First Quarter 2026 Financial Statements, please see BeOne’s Quarterly Report on Form 10-Q for the first quarter of 2026 filed with the U.S. Securities and Exchange Commission.

Updated Full Year 2026 Guidance

BeOne’s financial guidance is summarized below:¹

Assumes May 1, 2026 foreign exchange rates.²

Does not assume any potential new, material business development activity or unusual/non-recurring items.³

Non-GAAP operating income is a financial measure that excludes from the corresponding GAAP measure costs related to share-based compensation, depreciation and amortization expense. Guidance assumes that Non-GAAP expenses track overall expense growth.... (truncated)nd research at a pace that continues to deliver meaningful operating leverage.

The Company is providing the following additional guidance on items impacting net income and earnings per ADS:

• Other income (expense):

Estimated range of $25 million to $50 million in expense, includes interest amortization from Royalty Pharma arrangement.

• Income tax outlook

: Earnings may provide sufficient positive evidence to reverse certain valuation allowances in 2026, resulting in a material tax benefit when recognized; the timing and magnitude of a potential reversal is uncertain; prior to reversal, income tax expense should trend with earnings per historical relationship. See Form 10-Q for additional updates on income tax uncertainties.

• Diluted ADS outstanding:

The Company expects diluted ADSs outstanding of approximately 118 million.

First Quarter 2026 Business Highlights

Core Marketed Products

BRUKINSA (zanubrutinib)

• Received Orphan Drug Designation in Japan for the treatment of adult patients with relapsed or refractory (R/R) marginal zone lymphoma (MZL).

• Submitted New Drug Application in Japan for R/R MZL and tablet formulation.

Sonrotoclax (BCL2 inhibitor)

• Launched and commercially available in China for the treatment of adult patients with R/R mantle cell lymphoma (MCL) and R/R chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).

• Included in the European Society of Medical Oncology (ESMO) guidelines as a recommended third-line treatment for R/R MCL patients.

TEVIMBRA (tislelizumab)

• Received acceptance of a Supplemental Biologics License Application (sBLA) by the U.S. Food and Drug Administration (FDA) with Priority Review for the treatment of adult patients with first-line HER2-positive gastroesophageal adenocarcinoma (

GEA) in combination with

ZIIHERA ( zanidatamab) and chemotherapy, based on results of the

HERIZON-GEA-01 trial which demonstrated statistically significant and clinically meaningful improvement in overall survival versus trastuzumab plus chemotherapy.

• Received acceptance of sBLA by the Center for Drug Evaluation (CDE) in China for the treatment of adult patients with first-line HER2-positive GEA in combination with ZIIHERA and chemotherapy.

ZIIHERA (zanidatamab)

• Received acceptance of sBLA by the CDE in China for the treatment of adult patients with first-line HER2-positive GEA in combination with chemotherapy, with or without TEVIMBRA.

Select Clinical-Stage Programs

Hematology

• BGB-16673 (BTK CDAC): Initiated Phase 2 cohorts in R/R MZL and Richter’s Transformation.

Breast and Gynecological Cancers

• BGB-43395 (CDK4 inhibitor): Received acceptance of Phase 1 study data as a poster presentation at ASCO.

• BG-C9074 (B7-H4 ADC): Received acceptance of Phase 1 study data as a rapid oral presentation at ASCO.

Gastrointestinal Cancers

• BGB-B2033 (GPC3x41BB bispecific antibody):

◦ Received FDA Orphan Drug Designation for hepatocellular carcinoma (HCC).

◦ Initiated potentially registrational study in patients with HCC.

◦ Received acceptance of Phase 1 study data as a rapid oral presentation at ASCO.

Lung Cancer

• BG-C0979 (ADAM9-targeting ADC): Initiated first-in-human study.

Inflammation and Immunology

• BG-A3004 (KLRG1 mAb): Initiated first-in-human study.

Anticipated R&D Milestones

Corporate Updates

• Entered into an exclusive option with Huahui Health to license worldwide rights to HH160 (BON-110), a novel trispecific antibody targeting PD-1, VEGF-A and CTLA-4.

BeOne’s Earnings Results Webcast

The Company’s earnings conference call for the first quarter 2026 will be broadcast via webcast at 8:00 a.m. ET on Wednesday, May 6, 2026, and will be accessible through the Investors section of BeOne’s website at www.beonemedicines.com. Supplemental information in the form of a slide presentation, transcript of prepared remarks, and a replay of the webcast will also be available.

About BeOne

BeOne Medicines is a global oncology company that is discovering and developing innovative treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The Company has a growing global team spanning six continents who are driven by scientific excellence and exceptional speed to reach more patients than ever before.

To learn more about BeOne, please visit www.beonemedicines.com and follow us on LinkedIn, X, Facebook and Instagram.

Financial statements

Income Statement

Three Months Ended — (Amounts in thousands of U.S. dollars and unaudited)

Three Months Ended – March 31, – 2026Three Months Ended – March 31, – 2025% Change
Net product revenues1,487,3291,108,53034.0%
Other revenue26,1098,749198.0%
Total revenue1,513,4381,117,27935.0%
GAAP income from operations249,90211,1022151.0%
Adjusted income from operations*414,394139,357197.0%
GAAP net income227,3571,27017802.0%
Adjusted net income*375,042136,137175.0%
GAAP basic EPS per ADS2.050.0120400.0%
Adjusted basic EPS per ADS*3.381.27166.0%
GAAP diluted EPS per ADS1.960.0119500.0%
Adjusted diluted EPS per ADS*3.241.22166.0%
Free Cash Flow*160,547-12,3251403.0%

Income Statement

The following table summarizes operating expenses for the first quarter of 2026: (unaudited, in thousands, except percentages)

GAAP – Q1 2026GAAP – Q1 2025% ChangeNon-GAAP – Q1 2026Non-GAAP – Q1 2025% Change
Research and development541,224481,88712.0%465,904421,19511.0%
Selling, general and administrative555,097459,28821.0%471,993395,51119.0%
Total operating expenses1,096,321941,17516.0%937,897816,70615.0%

Income Statement

BeOne’s financial guidance is summarized below:

Prior FY 2026 GuidanceCurrent FY 2026 Guidance1
Total revenue$6.2 - $6.4 billion$6.3 - $6.5 billion
GAAP gross margin %High-80% rangeHigh-80% range
GAAP operating expenses2 (combined R&D and SG&A)$4.7 - $4.9 billion$4.7 - $4.9 billion
GAAP operating income2$700 - $800 million$750 - $850 million
Non-GAAP operating income2,3$1.4 - $1.5 billion$1.45 - $1.55 billion

Income Statement

Three Months Ended March 31, — (Amounts in thousands of U.S. dollars, except for shares, American Depositary Shares (ADSs), per share and per ADS data)

Three Months Ended March 31, – 2026 – (Unaudited)Three Months Ended March 31, – 2025 – (Unaudited)
RevenuesProduct revenue, net1,487,3291,108,530
RevenuesOther revenue26,1098,749
RevenuesTotal revenues1,513,4381,117,279
RevenuesCost of sales - products167,215165,002
RevenuesGross profit1,346,223952,277
Operating expenses:Research and development541,224481,887
Operating expenses:Selling, general and administrative555,097459,288
Operating expenses:Total operating expenses1,096,321941,175
Operating expenses:Income from operations249,90211,102
Operating expenses:Interest income27,66412,850
Operating expenses:Interest expense-32,887-7,002
Operating expenses:Other income, net14,5363,950
Operating expenses:Income before income taxes259,21520,900
Operating expenses:Income tax expense31,85819,630
Operating expenses:Net income227,3571,270
Earnings per shareBasic0.160
Earnings per shareDiluted0.150
Earnings per shareWeighted-average shares outstanding—basic1,442,451,8701,390,052,966
Earnings per shareWeighted-average shares outstanding—diluted1,505,027,3381,445,253,219
Earnings per American Depositary Share (“ADS”)Basic2.050.01
Earnings per American Depositary Share (“ADS”)Diluted1.960.01
Earnings per American Depositary Share (“ADS”)Weighted-average ADSs outstanding—basic110,957,836106,927,151
Earnings per American Depositary Share (“ADS”)Weighted-average ADSs outstanding—diluted115,771,334111,173,325

Income Statement

Three Months Ended — (unaudited)

Three Months Ended – March 31, – 2026Three Months Ended – March 31, – 2025
Reconciliation of GAAP to adjusted cost of sales - products:GAAP cost of sales - products167,215165,002
Reconciliation of GAAP to adjusted cost of sales - products:Less: Depreciation4,3262,613
Reconciliation of GAAP to adjusted cost of sales - products:Less: Amortization of intangibles1,7421,173
Reconciliation of GAAP to adjusted cost of sales - products:Adjusted cost of sales - products161,147161,216
Reconciliation of GAAP to adjusted research and development:GAAP research and development541,224481,887
Reconciliation of GAAP to adjusted research and development:Less: Share-based compensation cost53,85641,767
Reconciliation of GAAP to adjusted research and development:Less: Depreciation21,46418,925
Reconciliation of GAAP to adjusted research and development:Adjusted research and development465,904421,195
Reconciliation of GAAP to adjusted selling, general and administrative:GAAP selling, general and administrative555,097459,288
Reconciliation of GAAP to adjusted selling, general and administrative:Less: Share-based compensation cost69,49253,684
Reconciliation of GAAP to adjusted selling, general and administrative:Less: Depreciation13,59510,076
Reconciliation of GAAP to adjusted selling, general and administrative:Less: Amortization of intangibles1717
Reconciliation of GAAP to adjusted selling, general and administrative:Adjusted selling, general and administrative471,993395,511
Reconciliation of GAAP to adjusted operating expensesGAAP operating expenses1,096,321941,175
Reconciliation of GAAP to adjusted operating expensesLess: Share-based compensation cost123,34895,451
Reconciliation of GAAP to adjusted operating expensesLess: Depreciation35,05929,001
Reconciliation of GAAP to adjusted operating expensesLess: Amortization of intangibles1717
Reconciliation of GAAP to adjusted operating expensesAdjusted operating expenses937,897816,706
Reconciliation of GAAP to adjusted income from operations:GAAP income from operations249,90211,102
Reconciliation of GAAP to adjusted income from operations:Plus: Share-based compensation cost123,34895,451

Income Statement

(Unaudited)(Unaudited)
Operating Income Guidance for Full Year 2026GAAP operating income750,000850,000
Operating Income Guidance for Full Year 2026Plus: Adjustments to arrive at Non-GAAP1700,000700,000
Operating Income Guidance for Full Year 2026Non-GAAP operating income1,450,0001,550,000

Balance Sheet

(Amounts in thousands of U.S. Dollars)

As of – March 31, – 2026 – (unaudited)As of – December 31, – 2025 – (audited)
Assets:Cash, cash equivalents and restricted cash4,853,4254,609,647
Assets:Accounts receivable, net938,019865,080
Assets:Inventories681,590608,227
Assets:Property, plant and equipment, net1,640,9181,641,678
Assets:Total assets8,553,6198,188,573
Liabilities and equity:Accounts payable423,546479,035
Liabilities and equity:Accrued expenses and other payables1,079,2831,109,120
Liabilities and equity:R&D cost share liability35,70064,345
Liabilities and equity:Sale of future royalty liability904,399906,956
Liabilities and equity:Debt1,078,6551,019,206
Liabilities and equity:Total liabilities3,793,1773,827,379
Liabilities and equity:Total equity4,760,4424,361,194

Cash Flow

Three Months Ended March 31, — (Amounts in thousands of U.S. Dollars)

Three Months Ended March 31, – 2026 – (unaudited)Three Months Ended March 31, – 2025 – (unaudited)
Cash, cash equivalents and restricted cash at beginning of period4,609,6472,638,747
Net cash provided by operating activities201,33644,082
Net cash used in investing activities-45,510-121,941
Net cash provided by (used in) financing activities68,632-33,777
Net effect of foreign exchange rate changes19,3203,480
Net increase (decrease) in cash, cash equivalents, and restricted cash243,778-108,156
Cash, cash equivalents and restricted cash at end of period4,853,4252,530,591

Cash Flow

Three Months Ended

Three Months Ended – March 31, – 2026Three Months Ended – March 31, – 2025
Free Cash Flow (Non-GAAP):Net cash provided by operating activities (GAAP)201,33644,082
Free Cash Flow (Non-GAAP):Less: Purchases of property, plant and equipment-40,789-56,407
Free Cash Flow (Non-GAAP):Free Cash Flow (Non-GAAP)160,547-12,325
Full release

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding: BeOne’s continued growth as a global oncology leader; the fixed-duration combination of sonrotoclax and BRUKINSA as a potential new standard-of-care in first-line CLL; the emergence of BGB-16673 as a potential first-in-class therapy for R/R CLL; BeOne’s future revenue, gross margin percentage, operating expenses, operating income, other income or expense, income tax and diluted ADS outstanding; BeOne’s expectations regarding continued global expansion and investment to support growth; upcoming R&D milestones to be achieved by BeOne; the timing of clinical and regulatory developments and data readouts; and BeOne’s plans, commitments, aspirations and goals under the caption “About BeOne.” Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including BeOne’s ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; BeOne’s ability to achieve commercial success for its marketed medicines and drug candidates, if approved; BeOne’s ability to obtain and maintain protection of intellectual property for its medicines and technology; BeOne’s reliance on third parties to conduct drug development, manufacturing, commercialization, and other services; BeOne’s limited experience in obtaining regulatory approvals and commercializing pharmaceutical products; BeOne’s ability to obtain additional funding for operations and to complete the development of its drug candidates and achieve and maintain profitability; and those risks more fully discussed in the section entitled “Risk Factors” in BeOne’s most recent periodic report filed with the U.S. Securities and Exchange Commission (“SEC”), as well as discussions of potential risks, uncertainties, and other important factors in BeOne’s subsequent filings with the SEC. All information in this press release is as of the date of this press release, and BeOne undertakes no duty to update such information unless required by law. BeOne’s financial guidance is based on estimates and assumptions that are subject to significant uncertainties.

Condensed Consolidated Statements of Operations (U.S. GAAP)

(Amounts in thousands of U.S. dollars, except for shares, American Depositary Shares (ADSs), per share and per ADS data)

Select Condensed Consolidated Balance Sheet Data (U.S. GAAP)

(Amounts in thousands of U.S. Dollars)

Select Condensed Consolidated Statements of Cash Flows (U.S. GAAP)

(Amounts in thousands of U.S. Dollars)

Note Regarding Use of Non-GAAP Financial Measures

BeOne provides certain non-GAAP financial measures, including Adjusted Operating Expenses, Adjusted Operating Loss, Adjusted Net Income, Adjusted Earnings Per Share, Free Cash Flow and certain other non-GAAP income statement line items, each of which include adjustments to GAAP figures. These non-GAAP financial measures are intended to provide additional information on BeOne’s operating performance. Adjustments to BeOne’s GAAP figures exclude, as applicable, non-cash items such as share-based compensation, depreciation and amortization. Certain other special items or substantive events may also be included in the non-GAAP adjustments periodically when their magnitude is significant within the periods incurred. Non-GAAP adjustments are tax effected to the extent there is U.S. GAAP current tax expense. The Company currently records a valuation allowance on its net deferred tax assets, so there is no net impact recorded for deferred tax effects. BeOne maintains an established non-GAAP policy that guides the determination of what costs will be excluded in non-GAAP financial measures and the related protocols, controls and approval with respect to the use of such measures. BeOne believes that these non-GAAP financial measures, when considered together with the GAAP figures, can enhance an overall understanding of BeOne’s operating performance. The non-GAAP financial measures are included with the intent of providing investors with a more complete understanding of BeOne’s historical and expected financial results and trends and to facilitate comparisons between periods and with respect to projected information. In addition, these non-GAAP financial measures are among the indicators BeOne’s management uses for planning and forecasting purposes and measuring BeOne’s performance. These non-GAAP financial measures should be considered in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. The non-GAAP financial measures used by BeOne may be calculated differently from, and therefore may not be comparable to, non-GAAP financial measures used by other companies.

RECONCILIATION OF SELECTED GAAP MEASURES TO NON-GAAP MEASURES

(Amounts in thousands of U.S. Dollars, except for per share and per ADS data)

(unaudited)¹

Tax effect of Non-GAAP adjustments is based on the statutory tax rate in the relevant tax jurisdiction. Please note that the Company currently records a valuation allowance on its net deferred tax assets, so there is no net impact recorded for deferred tax effects.

1.

The non-GAAP adjustments are based on best available information at this time related to non-cash items similar to those reported in our actual Non-GAAP results.

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · BeOne Medicines earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.